TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum tolerated dose of CDX-585
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CDX-585 by tumor type
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day use of electronic cigarettes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Remifentanil use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sprint for speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squat One-repetition maximum (1RM) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain SPECT Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Vaginal Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue - BRAF-MDQ
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fatigue - BRAF-NRS v2
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Western Ontario McMasters Universities Osteoarthritis index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early Ovarian Dysfunction Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 12-weeks Progression Free Proportion
Endpoint domain: Mortality/survival
Primary endpoint: 12-weeks Treatment Free Proportion
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients receiving Lung Cancer Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline of Time in Range (TiR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of oxygen desaturation <95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of MAD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beighton score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relative change of MDSCs in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of adverse events as measured by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who experienced dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline EuroQoL-5 Dimension (EQ-5D) Value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline Visual Analog Pain Scale (VAS) of Back Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: freedom from documented atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of 7-day neurological complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of 7-day stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of delayed awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rate of SGARI treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to discontinuation (days) of SGARI treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence of SGARI treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Microvascular AT2R Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Frequency of Medication Errors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline Health Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Therapeutic Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recovery from anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined retention and treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of key anatomical vascular features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identification of key pathological vascular features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Validity of the questionnaire (Q'SHY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity of the questionnaire (Q'SHY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Specificity of the questionnaire (Q'SHY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of days between randomization and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Up to date (UTD) status for all three screenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of follow-up for abnormal tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meal fat uptake in heart tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postpartum depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic and Diastolic Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of CEA conversion to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Active Shoulder Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with local injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with systemic reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Objectively assessed sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Objectively assessed sleep-onset latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Objectively assessed wake after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Objectively assessed sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Perceived stress level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Severity of obsessive-compulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Relapse of Takayasu Arteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent oxygen consumption at ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ventilatory efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of S. aureus skin microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum serum metronidazole concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum serum metronidazole concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum-concentration curve from 0-120 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency and severity of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in MEG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3D position of tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusal morphology of tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in laboratory design and in clinical delivery of denture prostheses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in depression measured with PHQ-9 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety measured with GAD-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with a metastatic lesion that have true malignancy
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients without metastatic lesion that do not have malignancy
Endpoint domain: Mortality/survival
Primary endpoint: clinically significant changes from baseline for vital signs: HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant changes from baseline for vital signs: SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant changes from baseline for vital signs: DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Skin Gammaproteobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Urinary albumin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of Sensor Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of back health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from Unanticipated Serious Adverse Device Effects (USADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Association between subclinical hypothyroidism and atherosclerotic cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantity/Frequency of Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self respiration recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye opening recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes assessed at 6 months of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Pain Scale (NIPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triage Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Return to Service
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete Medication Documentation at Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the concentration-time curve of midazolam in plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of midazolam in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndrome Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survey completion patterns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time spent in moderate-vigorous intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible patients for feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Reported Outcome of Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Outcome Measure of Genetic Counseling Visit Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Impact of CellSearch CTCs on treatment decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response assessment in MBC patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sequential finger tapping performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: shape-counting error
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Self-Reported Patient Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Self-Reported Patient Sexual Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Self-Reported Self-Efficacy for Coping with Sexual Concerns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The incidence of Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HT7 receptor expression on circulating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed 25-Foot Walk (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of non-adherent study participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Conversion surgery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EEG-ERP N400 in response to music stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Irritable Bowel Syndrome symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain relief score (TOTPARmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete regression (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of horizontal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Laboratory Test Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Central Retinal Thickness (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative first mobilization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of urinary NPHS2:Creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of individuals developing FPIES symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Success rate of gastroscopy/colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Achilles Tendon elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return of spontaneous circulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first call rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological Impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serious adverse device effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Magnetic Resonance Imaging Functional Brain Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of hesitant individuals who received a COVID-19 vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention behaviors of secondhand smoke exposure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Shared Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-28d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC7-28d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of TEAE and SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced OR time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Less Energy Transmission to Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Naloxone Behavioral Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Referral Behavioral Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Confiscation Behavioral Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: three-month follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lesion Detectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity index of seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety index of the incidence of adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Safety index of the incidence of abnormal blood biochemical indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SANDE questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time and amount of first postoperative rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to undergo genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10-year ASCVD risk Categorization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-year ASCVD risk Categorization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lifetime ASCVD risk evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alcohol preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient-reported fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximal clot elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of Nellcor Pulse Oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of withdrawal or down-titration of RAAS inhibition therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Force Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Success of Endoscopic Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Success of Endoscopic Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional hernia at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The level of seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of SLE Responder Index (SRI)4 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified MRC Dyspnea Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 6-MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning